指南与共识消化道肿瘤与早癌消化内镜

按拟议的美英联合风险分层指南的进展期结直肠肿瘤风险

Risk of advanced colorectal neoplasm by the proposed combined United States and United Kingdom risk stratification guidelines.
指南 / 共识 · Gastrointest Endosc · 2017-10-03

本研究纳入2570例结肠镜检查发现至少1枚腺瘤的患者,按腺瘤数量与组织学分为6组,比较3年时进展期结直肠肿瘤风险。结果显示≥5枚腺瘤且至少1枚进展期腺瘤组风险最高(9.6%),显著高于≥5枚非进展期腺瘤组(4.5%)和1至2枚腺瘤且至少1枚进展期腺瘤组(4.6%)。作者认为可对≥5枚腺瘤且至少1枚进展期腺瘤者建议比3年更密集的监测,对3至4枚非进展期腺瘤和≥5枚非进展期腺瘤者分别建议比3年和1年更宽松的监测。

要点

  • ≥5枚腺瘤且至少1枚进展期腺瘤组3年进展期结直肠肿瘤风险为9.6%。
  • ≥5枚非进展期腺瘤组风险为4.5%,与1至2枚腺瘤且至少1枚进展期腺瘤组(4.6%)无显著差异。
  • 结肠镜检查时超过1枚进展期腺瘤是进展期结直肠肿瘤的独立危险因素。

核心结论

  • 作者认为可对≥5枚腺瘤且至少1枚进展期腺瘤的患者建议比3年间隔更密集的监测。
  • 作者认为可对3至4枚非进展期腺瘤和≥5枚非进展期腺瘤的患者分别建议比3年和1年间隔更宽松的监测。

研究设计与样本

  • 研究纳入2570例在指数结肠镜检查时发现至少1枚腺瘤的患者。
  • 患者分为6组:第1组为1至2枚非进展期腺瘤(non-AAs)且无≥10毫米、高级别上皮内瘤变或绒毛状腺瘤;第1A组为1至2枚腺瘤且至少1枚进展期腺瘤(AA);第2组为3至4枚非进展期腺瘤;第2A组为3至4枚腺瘤且至少1枚进展期腺瘤;第3组为≥5枚非进展期腺瘤;第3A组为≥5枚腺瘤且至少1枚进展期腺瘤。
  • 比较6组在3年时进展期结直肠肿瘤(CRN)的风险。

主要发现

  • 第3A组进展期结直肠肿瘤风险为9.6%,高于第3组的4.5%(P = .03)和第1A组的4.6%(P < .001)。
  • 第3组进展期结直肠肿瘤风险为4.5%,与第1A组的4.6%(P = .91)和第2A组的6.8%(P = .25)均无显著差异。
  • 第1组与第2组进展期结直肠肿瘤风险分别为1.7%与2.2%,无显著差异(P = .22)。
  • 指数结肠镜检查时超过1枚进展期腺瘤是进展期结直肠肿瘤的独立危险因素。

临床怎么用

  • 作者认为可对≥5枚腺瘤且至少1枚进展期腺瘤的患者建议比3年间隔更密集的监测。
  • 作者认为可对3至4枚非进展期腺瘤的患者建议比3年间隔更宽松的监测。
  • 作者认为可对≥5枚非进展期腺瘤的患者建议比1年间隔更宽松的监测。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The U.K. guidelines for risk stratification after colon polypectomy differ from the U.S. guidelines in 2 ways: the U.K. guidelines consider ≥5 adenomas as high risk and do not consider histology (villous or high-grade dysplasia) in the assessment. Thus, we aimed to investigate the risk of advanced colorectal neoplasm (CRN) by categorized risk groups, considering both ≥5 adenomas and histology. METHODS: A total of 2570 patients with ≥1 adenoma at index colonoscopy were included. The patients were divided into 6 groups: group 1, 1 to 2 non-advanced adenomas (non-AAs) ≥10 mm or high-grade dysplasia or villous adenoma; group 1A, 1 to 2 adenomas with ≥1 advanced adenoma (AA); group 2, 3 to 4 non-AAs; group 2A, 3 to 4 adenomas with ≥1 AA; group 3, ≥5 non-AAs; and group 3A, ≥5 adenomas with ≥1 AA. The risk of advanced CRN at 3 years was compared among the 6 groups. RESULTS: Group 3A showed a higher risk of advanced CRN (9.6%) than group 3 (4.5%; P = .03) and group 1A (4.6%; P < .001). The risk of advanced CRN in group 3 (4.5%) showed no difference compared with group 1A (4.6%; P = .91) or group 2A (6.8%; P = .25). There was no difference between group 1 and group 2 in the risk of advanced CRN (1.7% vs 2.2%; P = .22). More than 1 AA at index colonoscopy was an independent risk factor for advanced CRN. CONCLUSION: More-intensive surveillance than the 3-year interval for patients with ≥5 adenomas with ≥1 AA and less-intensive surveillance than the 3-year and 1-year intervals for those with 3 to 4 non-AAs and ≥5 non-AAs, respectively, might be suggested.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Park SK, Yang HJ, Jung YS, et al. Risk of advanced colorectal neoplasm by the proposed combined United States and United Kingdom risk stratification guidelines. Gastrointest Endosc. 2017. PMID: 28986265. doi:10.1016/j.gie.2017.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。